copanlisib + gemcitabine

Copanlisib + gemcitabine is an experimental combination regimen of two anticancer drugs: copanlisib, a reversible pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against the alpha and delta isoforms, and gemcitabine, a nucleoside analog that inhibits DNA synthesis. The combination has been investigated in early-phase clinical trials for relapsed or refractory peripheral T-cell lymphoma (PTCL) and for advanced biliary tract cancers (BTC), based on evidence that PI3K/AKT pathway activation can contribute to resistance to chemotherapy, and simultaneous inhibition may enhance efficacy. Clinical trials have demonstrated manageable toxicity profiles with common adverse events including hyperglycemia, neutropenia, and thrombocytopenia. Efficacy outcomes include an overall response rate of up to 72% in PTCL, and response rates around 6-10% in advanced solid malignancies including BTC, although the combination did not extend progression-free survival compared to standard chemotherapies in BTC studies[1][2][3].